Cargando…

Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review

The pharmacokinetics of beta-lactam antibiotics in intensive care patients may be profoundly altered due to the dynamic, unpredictable pathophysiological changes that occur in critical illness. For many drugs, significant increases in the volume of distribution and/or variability in drug clearance a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sime, Fekade Bruck, Roberts, Michael S, Peake, Sandra L, Lipman, Jeffrey, Roberts, Jason A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460787/ https://www.ncbi.nlm.nih.gov/pubmed/22839761 http://dx.doi.org/10.1186/2110-5820-2-35

Ejemplares similares

How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
por: Wong, Gloria, et al.
Publicado: (2014)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

Continuous beta-lactam infusion in critically ill patients: the clinical evidence
por: Abdul-Aziz, Mohd H, et al.
Publicado: (2012)

Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction
por: Sime, Fekade B., et al.
Publicado: (2019)

Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections
por: Abdul-Aziz, Mohd H., et al.
Publicado: (2017)

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
por: Sime, Fekade B., et al.
Publicado: (2019)

A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
por: Sime, Fekade B., et al.
Publicado: (2019)

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients
por: Liu, Jiajun, et al.
Publicado: (2019)

Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
por: Veiga, Rui Pedro, et al.
Publicado: (2018)

Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain
por: Sime, Fekade B., et al.
Publicado: (2020)

SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients
por: Roberts, Jason A., et al.
Publicado: (2016)

743. Implementation of Beta-Lactam Therapeutic Drug Monitoring Programs in the Critically Ill: A Multicenter Mixed-Methods Study
por: Ausman, Sara, et al.
Publicado: (2022)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
por: Novy, Emmanuel, et al.
Publicado: (2023)

Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study
por: Barreto, Erin F., et al.
Publicado: (2021)

Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients—A Narrative Review
por: Stašek, Jan, et al.
Publicado: (2023)

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams
por: Gonçalves-Pereira, Joao, et al.
Publicado: (2011)

Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis
por: Pai Mangalore, Rekha, et al.
Publicado: (2022)

318. Beta-lactam Therapeutic Drug Monitoring Improves Attainment of Target Drug Levels in Critically Ill Patients
por: Ausman, Sara, et al.
Publicado: (2023)

Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients
por: Roberts, Jason A, et al.
Publicado: (2011)

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
por: Sime, Fekade B., et al.
Publicado: (2018)

Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?
por: Van Herendael, Bruno, et al.
Publicado: (2012)

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
por: Sime, Fekade Bruck, et al.
Publicado: (2016)

Are peripherally inserted central catheters in critical ill patients justified?
por: Martínez González, O, et al.
Publicado: (2015)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
por: Barbier, François, et al.
Publicado: (2023)

Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity
por: Legg, Amy, et al.
Publicado: (2023)

The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting
por: Pai Mangalore, Rekha, et al.
Publicado: (2023)

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2022)

Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy
por: Ulldemolins, Marta, et al.
Publicado: (2014)

Deep venous thrombosis Doppler screening in critically ill patients: is it justified?
por: Vlachou, I, et al.
Publicado: (2011)

Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis
por: Heffernan, Aaron, et al.
Publicado: (2021)

Challenges in Antifungal Therapy in Diabetes Mellitus
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2020)

Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
por: Barreto, Erin F., et al.
Publicado: (2021)

Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis
por: Billot, Laurent, et al.
Publicado: (2023)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach
por: Maguigan, Kelly L., et al.
Publicado: (2021)

Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations
por: Jager, Nynke G L, et al.
Publicado: (2020)

Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients
por: Van Daele, Ruth, et al.
Publicado: (2021)

Beta lactam hypersensitivities
por: Azoury, Marie Eliane*, et al.
Publicado: (2014)

We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
por: Cotta, Menino Osbert, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5gdgepqf6urs08o44bjkmj7nti